Abstract:Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. The in vitro activity of two new fluoroquinolones, delafloxacin and finafloxacin, were evaluated against M. hominis and Ureaplasma spp. The MICs of delafloxacin, finafloxacin, and two classical fluoroquinolones (moxifloxacin and levofloxacin) were tested against 29 M. hominis and 67 Ureaplasma spp. isolates using the broth microdilution method. The molecular mechanisms underlying fluoroquinolone resistance were also investigated. Delafloxacin exhibited low MICs against M. hominis and Ureaplasma spp., including the levofloxacin-resistant isolates. For M. hominis, delafloxacin showed low MIC90 value of 1 mu g/mL (MIC range, <0.031 -1 mu g/mL) compared to 8 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 mu g/mL for levofloxacin. For U. parvum and U. urealyticum, delafloxacin had low MIC90 values (U. parvum, 2 mu g/mL; U. urealyticum, 4 mu g/mL) compared to 16 -32 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 - >32 mu g/mL for levofloxacin. The two mutations GyrA S153L and ParC S91I were commonly identified in fluoroquinolone-resistant M. hominis, and ParC S83L was the most frequent mutation identified in fluoroquinolone-resistant Ureaplasma spp. Delafloxacin displayed lower MICs against fluoroquinolone-resistant isolates of both M. hominis and Ureaplasma spp. that have mutations in the quinolone resistance determining regions (QRDRs) than the two classical fluoroquinolones. Delafloxacin is a promising fluoroquinolone with low MICs against fluoroquinolone-resistant M. hominis and Ureaplasma spp. Our study confirms the potential clinical use of delafloxacin in treating antimicrobial-resistant M. hominis and Ureaplasma spp. infections. IMPORTANCE Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. Delafloxacin and finafloxacin displayed different antimicrobial susceptibility profiles against M. hominis and Ureaplasma spp. in vitro. Delafloxacin was found to be more effective against M. hominis and Ureaplasma spp. than three classical fluoroquinolones (finafloxacin, moxifloxacin, and levofloxacin). Finafloxacin displayed activity similar to moxifloxacin but superior to levofloxacin against M. hominis and Ureaplasma spp. Our findings demonstrate that delafloxacin is a promising fluoroquinolone with outstanding activity against fluoroquinolone-resistant M. hominis and Ureaplasma spp.

In vitro and in vivo activity of tosufloxacin

In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China

<i>In Vitro</i> Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and <i>Ureaplasma</i> Species

Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis

In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections

The Serum Bactericidal Activity of Gatifloxacin

In vitro antibacterial activity of Du6859a

Comparative Activities of Sitafloxacin Against Recent Clinical Isolates in Hospitals Across China

Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species

In vitro activity of cefminox and comparators against Escherichia coli, Klebsiella pneumoniae and Bacteroides species

Study in Vitro of Antimicrobial Activity of Domestic Sparfloxacin

Antimicrobial activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria

In vitro activity of gatifloxacin compared with 8 comparators against the Ureaplasma strains isolated from Shanghai, China

In Vitro Antibacterial Activity of Cefminox

[The Antibacterial Activity of Cefmetazole and Other Antibiotics to 463 Isolates].

A Clinical Drug Library Screen Identifies Tosufloxacin As Being Highly Active Against Staphylococcus Aureus Persisters

In vitro antibacterial activity study of gemifloxacin mesylate for injection

Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers

Antibacterial Mechanisms and Clinical Impact of Sitafloxacin

A Randomized Controlled Clinical Study on Levofloxacin Versus Ciprofloxacin in the Treatment of Bacterial Infections